February 15, 2015 / by / News
SolAeroMed managment and clinicians are attending, presenting SolAeroMed technology at the following conferences in 2015. Respiratory Drug Delivery, Antibes, Francis: May 5-8 2015 (unconfirmed) American Thoracic Society, Denver: May 15-20, 2015 (confirmed) BIO2015, Philadelphia: June 15-18, 2015 (unconfirmed) European Respiratory Society, Amsterdam: Sept 26-30, 2015 (confirmed) Respiratory Drug Delivery, Phoenix: April 17-21 2016 (confirmed)
Read more
SolAeroMed Announces Positive Proof-of-Concept Data for Its Lead Drug (S-1226) in Subjects with Mild Atopic Asthma
May 30, 2016 / by / News
CALGARY, Alberta, May 30, 2016 – SolAeroMed Inc. (“SolAeroMed”), a Calgary-based biotechnology company dedicated to developing novel drugs and devices to treat respiratory diseases, today announced positive Phase IIa proof-of-concept results for its S-1226 lead therapeutic. The Phase IIa study was a placebo-controlled, randomized, double-blind, crossover single dose study to evaluate the safety, tolerability and efficacy of S-1226 (8%)
Read more
SolAeroMed Announces Completion of Phase IIA Proof of Concept Recruitment for S-1226
November 24, 2015 / by / News
CALGARY, Alberta, November 24, 2015 – SolAeroMed Inc., dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases, today announced its completion of patient recruitment for core components of its Phase IIa Proof of Concept data for its S-1226™ technology by late Fall 2015. “We are very pleased the clinical trial site
Read more
European Respiratory Society Conference
September 23, 2015 / by / News
SolAeroMed Inc will be attending the European Thoracic Society conference in Amsterdam, Netherlands to present their S-1226 drug and device technologies. Abstract for S-1226 Drug: We have discovered a new short acting bronchodilator represents a new class of bronchodilator. The drug, S-1226, is made up of a gas (4-12% CO2 in air) combined with a synthetic
Read more
American Thoracic Society Conference
June 1, 2015 / by / News
SolAeroMed management and clinicians attended the American Thoracic Society in Denver, Colorado to present an overview of their current technologies, with a focus on the lead S-1226 drug. The abstract for the presentation can be accessed at: http://www.atsjournals.org/doi. The poster is available here: ATS 2015 Poster
Read more
Investment and partnering
March 2, 2015 / by / News
Dr John Dennis, CEO Background SolAeroMed Inc.’s (“SAMi”) drug candidate S-1226 has been under development by the company’s scientific founders since the early 1990s. Their work into the mechanisms underlying a surge in the western Canadian provinces of asthma-related deaths led to the discovery of a novel therapeutic intervention. Patent applications were filed in December
Read more
Conference networking 2015
February 15, 2015 / by / News
SolAeroMed managment and clinicians are attending, presenting SolAeroMed technology at the following conferences in 2015. Respiratory Drug Delivery, Antibes, Francis: May 5-8 2015 (unconfirmed) American Thoracic Society, Denver: May 15-20, 2015 (confirmed) BIO2015, Philadelphia: June 15-18, 2015 (unconfirmed) European Respiratory Society, Amsterdam: Sept 26-30, 2015 (confirmed) Respiratory Drug Delivery, Phoenix: April 17-21 2016 (confirmed)
Read more
S1226 Delivery Devices
February 2, 2015 / by / News
Our current clinical trials rely on a unique nebulizer system to delivery a consistent dose and concentration of S1226, and can be readily applied in clinic, Emergency Room and EMS settings. Operational aspects of S1226 neublizer system is demonstrated by John Dennis, SolAeroMed CEO, on this uTube video sponsorted by the nebulizer manufacturer, WestMed, at: http://www.youtube.com/watch?v=J6S6z71dZNk
Read more
SolAeroMed Newsletter #11
January 21, 2015 / by / News
SolAeroMed Shareholder Newsletter #11 January 21, 2015 Hello SAMi shareholders We write to provide an update on our evolving development at SolAeroMed (SAMi). Clinical Development: We had a productive and busy end to 2014 which included the formal start of our Phase IIa ‘proof of concept’ clinical trial which started December 16th in Calgary’s Foothills
Read more
S1226 Phase IIa initiated
January 19, 2015 / by / News
SolAeroMed submitted a Clinical Trial Application to Health Canada regulators and on Oct 23 obtained formal regualtory approval to proceed. Work with colleagues at the Foothills Hospital under direction of Prof Richard Leigh, SolAeroMed management with support from JSS consultants, to have all required drugs and documents in place. The official start date for this
Read more
JSS CRO in S-1226 Phase IIa
August 2, 2014 / by / News
JSS Research is a Contract Research Organization (CRO) based in Montreal with whom SolAeroMed is partnering to conduct our Phase IIa safety and effiacy trial on S-1226(8%). JSS Medical Research: Has over 25 years of experience in clinical research Has experience in more than 15 therapeutic areas Offers a full spectrum of services Is a
Read more